You are viewing the site in preview mode

Skip to main content

Advertisement

Table 4 Studies on thalidomide and derivatives.

From: Radiotherapy and "new" drugs-new side effects?

Substance Author(s) Year Study type N tumour RT dose/ChTx/technique Toxicity
Thalidomide Knisely et al. [93] 2008 Phase III 332 (90 thalidomide) Brain metastases 37,5 Gy (2,5 Gy) 53% interruptions because of side-effects
  Chang et al. [187] 2004 Phase II 67 GBM 60 Gy (2 Gy), TMZ concomitant 10% grade III + IV neutropenia, 1% grade V; 16% grade III + IV thrombopenia, 9% grade III + IV rash, 1% grade III constipation, 9% grade III fatigue
  Atkins et al. [188] 2008 Phase II 39 CNS metastases (melanoma) 30 Gy (3 Gy) WBRT + TMZ concomitant 10% grade III + IV + V thrombosis, 5% grade III + IV + V myelosuppression, 8% grade III + IV + V cardiac events
  Ch'ang et al. [189] 2011 Phase II 24 HCC 50 Gy (2 Gy) 54% rash, 38% somnolence, 33% constipation
  Turner et al. [97] 2007 Phase II 13 Brainstem glioma + GBM 55.8 Gy (1.8 Gy) 8% grade IV DVT, ≥ 15% grade III leukopenia/motoneuropathy/constipation
Lenalidomide Drappatz et al. [101] 2009 Pilot study 23 GBM 60 Gy (2 Gy) 4% grade IV pneumonitis/hypoxia, 9% grade III nausea, 4% grade IV pulmonary embolism, 4% grade III pneumonia
  1. N-number of patients, pt(s)-patient(s), n. r.-not reported, ChTx-chemotherapy, LA-HNSCC-locally advanced head-and-neck cancer, GBM-glioblastoma multiforme, DVT-deep vein thrombosis